A Phase 1 Open-label Study of the Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers
Phase of Trial: Phase I
Latest Information Update: 08 Jul 2019
Price : $35 *
At a glance
- Drugs Selinexor (Primary) ; Carboplatin; Paclitaxel
- Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 01 Jul 2019 Planned End Date changed from 1 Oct 2019 to 1 Oct 2020.
- 01 Jul 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Oct 2020.
- 26 Jun 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.